A Fred Hutchinson Cancer Center study, published in Obstetrics & Gynecology,investigated how endometriosis, uterine leiomyomas (also known as fibroids), and a common intervention for these conditions—hysterectomy—changed ovarian cancer risk in Black and white women.
EC granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. Elahere is the first and only folate receptor alpha-directed antibody drug conjugate medicine approved in the EU, as well as Iceland, Liechtenstein, Norway, and Northern Ireland.
